Optimized human intestinal organoid model reveals interleukin-22-dependency of paneth cell formation

Gui-Wei He,Lin Lin,Jeff DeMartino,Xuan Zheng,Nadzeya Staliarova,Talya Dayton,Harry Begthel,Willine J. van de Wetering,Eduard Bodewes,Jeroen van Zon,Sander Tans,Carmen Lopez-Iglesias,Peter J. Peters,Wei Wu,Daniel Kotlarz,Christoph Klein,Thanasis Margaritis,Frank Holstege,Hans Clevers

DOI: https://doi.org/10.1016/j.stem.2022.08.002

IF: 23.9

2022-09-02

Cell Stem Cell

Abstract:Opposing roles have been proposed for IL-22 in intestinal pathophysiology. We have optimized human small intestinal organoid (hSIO) culturing, constitutively generating all differentiated cell types while maintaining an active stem cell compartment. IL-22 does not promote the expansion of stem cells but rather slows the growth of hSIOs. In hSIOs, IL-22 is required for formation of Paneth cells, the prime producers of intestinal antimicrobial peptides (AMPs). Introduction of inflammatory bowel disease (IBD)-associated loss-of-function mutations in the IL-22 co-receptor gene IL10RB resulted in abolishment of Paneth cells in hSIOs. Moreover, IL-22 induced expression of host defense genes (such as REG1A, REG1B, and DMBT1) in enterocytes, goblet cells, Paneth cells, Tuft cells, and even stem cells. Thus, IL-22 does not directly control the regenerative capacity of crypt stem cells but rather boosts Paneth cell numbers, as well as the expression of AMPs in all cell types.

cell biology,cell & tissue engineering